| Filed On | Filing |
|---|---|
| 18 May 2026 |
8-K: Termination of a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +5 more
Section 1. Registered Office. The registered office of the corporation in the State of Delaware is 251 Little Falls Drive, City of Wilmington, County of New Castle, 19808 or in such other location as the Board of Directors of the corpora... |
| 07 Apr 2026 |
8-K: Other Events
On April 7, 2026, Soleno Therapeutics, Inc. (the “Company”) reported that it has voluntarily withdrawn its marketing authorization application (“MAA”) for VIOKAT prolonged-release tablets (diazoxide choline), which is marketed in the Uni... |
| 06 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
This AGREEMENT AND PLAN OF MERGER (this “Agreement”), is made and entered into as of April 5, 2026, by and among Neurocrine Biosciences, Inc., a Delaware corporation (“Parent”), Sigma Merger Sub, Inc., a Delaware corporation and a direct... |
| 16 Mar 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
The registered office of Soleno Therapeutics, Inc. shall be fixed in the corporation’s certificate of incorporation. References in these bylaws to the certificate of incorporation shall mean the certificate of incorporation of the corpor... |
| 26 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
I am pleased to offer you a position with Soleno Therapeutics, Inc., a Delaware corporation (the “Company”), as Chief Financial Officer. This position requires onsite presence at our headquarters in Redwood City, CA one week per month, c... |
| 25 Feb 2026 |
8-K: Results of Operations and Financial Condition
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR |
| 23 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
1. Introduction. This Soleno Therapeutics, Inc. Key Executive Change in Control and Severance Plan (as may be amended from time to time, this “Plan”) has been adopted by Soleno Therapeutics, Inc. (the “Company”), effective as of January ... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition
REDWOOD CITY, Calif., January 12, 2026 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced select preliminary financial and op... |
| 12 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
This master confirmation (this “Master Confirmation”), dated as of November 10, 2025, sets forth certain terms and conditions of certain Transactions (each, a “Transaction”) that Jefferies LLC (“Jefferies”), will enter into with Soleno T... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
REDWOOD CITY, Calif., November 4, 2025 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the third quar... |
| 14 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Appointment adds three decades of financial and operational leadership to Soleno’s Board |
| 10 Sep 2025 |
8-K: Regulation FD Disclosure
Soleno Therapeutics, Inc. is aware that a serious adverse event has been reported in the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System (FAERS) regarding a patient who is deceased. The treating physician has rep... |
| 18 Aug 2025 |
8-K: Regulation FD Disclosure
Corporate Presentation August 2025 | Soleno Therapeutics Exhibit 99.1 |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
REDWOOD CITY, Calif., August 6, 2025 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATT... |
| 11 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, |
| 10 Jul 2025 |
8-K: Results of Operations and Financial Condition
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today certain preliminary u... |
| 06 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 5, 2025, Soleno Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders. Of the 49,908,303 shares of common stock outstanding as of April 15, 2025, the record date, 47,273,966 shares of common stock were r... |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
REDWOOD CITY, Calif., May 7, 2025 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM X... |
| 18 Apr 2025 |
8-K: Changes in Registrant's Certifying Accountant
We have read the statements made by Soleno Therapeutics, Inc. under Item 4.01 of its Form 8-K dated April 18, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with oth... |
| 26 Mar 2025 |
8-K: Results of Operations and Financial Condition
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome |
Loading...